Company:  VERTEX PHARMACEUTICALS IN ... (VRTX)
Form Type:  4
Filing Date:  6/3/2020 
CIK:  0000875320 
Address:  50 NORTHERN AVENUE 
City, State, Zip:  BOSTON, Massachusetts 02210 
Telephone:  (617) 341-6393 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$273.34  
Change: 
0.11 (0.04%)  
Trade Time: 
Aug 06  
Market Cap: 
$71.20B
Trade VRTX now with 

© 2020  
Description of Business
We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. Cystic Fibrosis Our goal is to develop treatment regimens that will provide benefits to all patients with cystic fibrosis, or CF, and will enhance the benefits that currently are being provided to patients taking our medicines. Our marketed medicines are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). We obtained approval from the U.S. Food and Drug Administration, or the FDA, for TRIKAFTA, our triple combination regimen, in October 2019. This approval increased the number of patients eligible for our medicines in the U.S. by approximately 6,000 and provided an additional treatment option for many patients who are also eligible for one of our previously approved products.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES
  EXHIBIT 24
    POWER OF ATTORNEY